The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | The RELEVANCE study: lenalidomide plus rituximab vs. rituximab-chemotherapy in the treatment of FL
In this video, Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, briefly highlights findings from the RELEVANCE study (NCT01650701), which compared lenalidomide plus rituximab versus rituximab-chemotherapy in patients with previously untreated follicular lymphoma. Although the results of this study were negative, Dr Nastoupil mentions the importance of further investigating chemotherapy-free options for patients with follicular lymphoma, and that the results from this study provide valuable information. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
